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Background 
Unlike many other childhood cancers, genomic abnormalities are not used in the clinical management of 
paediatric Burkitt lymphoma (BL) and few prognostic biomarkers have been identified. In sporadic BL gain of 
chromosome 7 and deletion of 13q are the only abnormalities that have been associated with an adverse 
prognosis in the context of a clinical trial. Gains of 13q have also been reported, including gain of the miR17HG 
locus, but the prognostic value in endemic BL is unknown. 
 
Objectives 
To test the prognostic value of chromosome 7 and 13q abnormalities in a clinically annotated cohort of endemic 
Burkitt lymphomas.  
 
Methods 
Fine-needle aspirates from 80 endemic BL patients were screened for chromosome 7 and 13 copy number 
abnormalities. The genomic breakpoints of the detected abnormalities were mapped using Affymetrix Oncoscan 
arrays and the genomic landscape investigated.  
 
Results 
Gain of chromosome 7 and deletion of 13q were identified in 2/59 (3%) and 1/58 (2%) samples, respectively. 
All 3 patients had an adverse outcome. Gains of 13q were detected in 5/64 (8%) samples, and 9/57 (16%) of 
patients had gain of the miR17HG locus. miR17HG gain is associated with a significant decrease in 12 month 
event-free survival (p <0.05 log rank). 7/9 patients either relapsed or died of disease. There is an increased risk 
of an adverse event occurring in patients with miR17HG gain during the first 6 months after diagnosis (hazard 
ratio 2.851; 95% confidence interval, 1.138-7.14; p=0.025). Genomic analysis of patients with chr7 and 13 
abnormalities revealed a complex genome and identified recurrent abnormalities.   
 
Conclusion 
We have identified the first molecular marker of adverse outcome in endemic Burkitt lymphoma and shown that 
gain of the miR17HG locus infers an increased risk of an adverse event within 6 months of diagnosis.  
 
